Resveratrol Senolytic Evidence: The Disappointing Human Data

Expert Summary

Resveratrol's promise as an anti-aging compound was based on SIRT1 activation (later disputed in mechanism) and lifespan extension in simple organisms. Human clinical trials have consistently failed to replicate benefits observed in animal models, primarily because resveratrol's oral bioavailability in humans is <1% — making plasma concentrations far below the concentrations producing biological effects in vitro.

Key Facts

• Bioavailability problem: Resveratrol is rapidly conjugated to glucuronide and sulfate metabolites in the gut and liver. <1% of oral resveratrol reaches systemic circulation as free (bioactive) resveratrol. At standard doses (100–500 mg), plasma free resveratrol is in the low nanomolar range — 100–1,000x below effective concentrations in cell culture.
• SIRT1 controversy: David Sinclair's original SIRT1 activation papers were challenged by GSK researchers who could not replicate direct SIRT1 activation by resveratrol. The SIRT1-activating mechanism may be indirect (via AMPK) rather than the direct binding originally proposed.
• Human trial results: The Conquer trial (250 mg/day, healthy older adults), CALERIE trial (with resveratrol), and multiple cardiovascular trials found no significant benefit vs placebo for metabolic markers, cognitive function, or inflammatory biomarkers.
• Dosing problems: To achieve plasma concentrations from animal studies in humans would require >5,000 mg/day — impractical and associated with GI side effects.
• What resveratrol does work for: Some human evidence exists for very high doses (500–2,000+ mg/day) reducing inflammatory markers in specific populations (metabolic syndrome, fatty liver). These require impractical doses.
• Pterostilbene alternative: Pterostilbene (methylated resveratrol analog with 80% bioavailability) delivers what resveratrol promises but fails to provide at oral doses in humans.

Recommended Products

Frequently Asked Questions

Is resveratrol a waste of money?

For the typical 100–200 mg/day doses in most supplements, yes — plasma levels are too low to replicate animal model effects. If taking resveratrol, use high-dose formats (500+ mg) or switch to pterostilbene for reliably higher bioavailability.

Did Sinclair's resveratrol research mislead people?

The science was conducted in good faith; translation from simple organisms to humans encountered the common problem of poor human bioavailability. The SIRT1 mechanism question is ongoing. Sinclair has since shifted focus to NMN and other compounds.

Scientific References

• Tomé-Carneiro J et al. Resveratrol and clinical trials: the crossroads from in vitro studies to human evidence. Current Pharmaceutical Design. 2013. PMID: 23470237